Immuno-Oncology Combinations in Advanced RCC: Building on Recent Progress for Community Practices (6/25/2020)

Click the Take Course button to access the evaluation.

 

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

New Therapeutic Developments in Urothelial Cancer: Clinical Trial Evidence and Expert Guidance

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with urothelial cancer.

Practical Application of Immuno-Oncology in Renal Cell Carcinoma (6/26/2020)

The goal of this activity is to improve participants’ competence in and performance at applying practice-changing clinical data, expert recommendations, and guidelines to optimize the use of immuno-oncology–based combinations in the care of their patients with RCC.

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Head and Neck Cancer
Health-related quality of life issues are paramount in head and neck (H&N) cancers, since these tumors affect basic physiologic functions (i.e., the ability to chew, swallow, and breathe), the senses (i.e., taste, smell, hearing), and uniquely human characteristics (i.e., appearance, voice).
Practical Application of Immuno-Oncology in Renal Cell Carcinoma (6/16/2020)

The goal of this activity is to improve participants’ competence in and performance at applying practice-changing clinical data, expert recommendations, and guidelines to optimize the use of immuno-oncology–based combinations in the care of their patients with RCC.

NCCN Pharmacy Updates: Emerging Strategies in the Treatment of Venous Thromboembolism
Expanded indications for the use of the direct oral anticoagulants demand diligent monitoring. Health care professionals play a crucial role in the management of anticoagulation in cancer patients and anticoagulation monitoring clinics may need to rechannel resources to include these agents.
NCCN Pharmacy Updates: Treatment Advances for Pediatric B-Cell Non-Hodgkin's Lymphomas
This is a potentially curable malignancy and systemic therapy is the mainstay of treatment. Understanding the diagnosis, workup, and subsequent treatment for early stage and later stage disease will improve understanding and subsequently, education for patients and caregivers alike.
NCCN Pharmacy Updates: Establishing a Place in Therapy for Biosimilars in Oncology
Clinical oncology pharmacists have the opportunity to provide education on biosimilars and be a part of the multi-disciplinary decision-making process for incorporating biosimilars into practice sites. In addition, pharmacists will need training on reporting post-marketing surveillance data regarding immunogenicity, product variability and drift of biosimilars as use becomes widespread.
NCCN Pharmacy Updates: Novel Treatments for Neuroendocrine Tumors
While there is a brand new treatment option for neuroendocrine tumors, it requires a wide array of practical guidance to be given safely and effectively.  Practitioners need to be well versed in patient eligibility, patient preparation for treatment, dosing, administration, and management of side effects.
NCCN Pharmacy Updates: Assessment and Management of CAR T-Cell Related Toxicities
CAR T-cell products have the ability to completely change the treatment paradigm for hematologic malignancies.  These therapies are associated with life-threatening toxicities that require rapid intervention. Newly published consensus statements to better define and grade these toxicities should be incorporated into clinical practice.

Pages

Subscribe to RSS - Live Webinar